Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2023 Jul 8;23(1):454.
doi: 10.1186/s12879-023-08422-6.

Real-world use of remdesivir for the treatment of patients admitted to Italian hospitals with COVID-19: the nationwide retrospective FADOI-RECOVER study

Filippo Pieralli #  1 , Fulvio Pomero #  2 , Francesco Dentali  3 , Claudio Norbiato  4 , Tiziana Attardo  5 , Susanna Vicari  6 , Elena Magnani  7 , Maria Antonietta Marzilli  8 , Paola Piccolo  9 , Antonella Valerio  10 , Dario Manfellotto  9   11 ; FADOI RECOVER Study Group
Collaborators, Affiliations
Observational Study

Real-world use of remdesivir for the treatment of patients admitted to Italian hospitals with COVID-19: the nationwide retrospective FADOI-RECOVER study

Filippo Pieralli et al. BMC Infect Dis. .

Abstract

Background: Remdesivir is widely used for treatment of SARS-CoV-2 pneumonia. The aim of this study was to evaluate the characteristics of patients with moderate-to-severe COVID-19 treated with remdesivir, and their outcomes during hospitalization.

Methods: This retrospective observational multicenter study included consecutive patients, hospitalized for moderate-to-severe COVID-19 (September 2020-September 2021), who were treated with remdesivir.

Results: One thousand four patients were enrolled, all with onset of symptoms occurring less than 10 days before starting remdesivir; 17% of patients had 4 or more concomitant diseases. Remdesivir was well tolerated, adverse drug reactions (ADRs) being reported in 2.3% of patients. In-hospital death occurred in 80 patients (8.0%). The median timing of the first remdesivir dose was 5 days after symptom onset. The following endpoints did not differ according to the time span from the onset of symptoms to the first dose: length of hospitalization, in-hospital death, composite outcome (in-hospital death and/or endotracheal intubation). Advanced age, number of comorbidities ≥ 4, and severity of respiratory failure at admission were associated with poor in-hospital outcomes.

Conclusion: In a real-world setting, remdesivir proved to be a safe and well-tolerated treatment for moderate-to-severe COVID-19. In patients receiving remdesivir less than 3 or 5 days from the onset of SARS-CoV-2 symptoms, mortality and the need for mechanical ventilation did not differ from the rest of the sample.

Keywords: COVID-19 pneumonia; Internal Medicine; Management of COVID-19; Remdesivir.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

References

    1. World Health Organization. WHO Coronavirus (COVID-19) Dashboard Homepage. Available from: https://covid19.who.int/ [cited 2023].
    1. Pieralli F, Vannucchi V, Olivotto I. The eighth alternative to evidence based medicine in the early era of the COVID-19 pandemic: too much Emergency and Emotion, too little Evidence. Eur J Intern Med. 2020;77:163–164. doi: 10.1016/j.ejim.2020.05.040. - DOI - PMC - PubMed
    1. First COVID-19 treatment recommended for EU authorization. European Medicines Agency. 2020. https://www.ema.europa.eu/en/news/first-covid-19-treatment-recommended-e.... Accessed on 25 Jun 2020.
    1. Siegel D, Hui HC, Doerffler E, Clarke MO, Chun K, Zhang L, Neville S, et al. Discovery and synthesis of a phosphoramidate prodrug ofa pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of Ebola and emerging viruses. J Med Chem. 2017;60(5):1648–1661. doi: 10.1021/acs.jmedchem.6b01594. - DOI - PubMed
    1. Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski L, Case JB, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9(396):e3653. doi: 10.1126/scitranslmed.aal3653. - DOI - PMC - PubMed

Publication types